Immunome Inc

Explore Immunome Inc.’s biotech focus, Nasdaq performance, and volatility‑driven merger‑related gains—ideal for investors eyeing Pennsylvania‑based growth.

Immunome’s Varegacestat clinches Phase‑3 success in desmoid tumors, catapulting shares over 30% and positioning the biotech as a breakthrough player in a niche market.

Immunome, Inc. is a Pennsylvania-based biotechnology company developing innovative therapeutic antibodies and medicines, with a market capitalization of $915.37 million and a promising future in the health care sector.

Immunome, Inc. is a biotechnology company that is pioneering the development of novel therapeutic antibodies and medicines, offering new hope to patients and solidifying its position as a key player in the industry.

Immunome Inc. is a biotechnology company focused on developing and commercializing novel therapeutic antibodies and medicines, with a market capitalization of $770.92 million USD.